Histone deacetylase inhibitors and phenotypical transformation of cancer cells

Cancers

Volumn 11, Issue 2, 2019, Pages

  Wawruszak, Anna ^a   Kalafut, Joanna ^a   Okon, Estera ^a   Czapinski, Jakub ^a,b   Halasa, Marta ^a   Przybyszewska, Alicja ^a   Miziak, Paulina ^a   Okla, Karolina ^a   Rivero Muller, Adolfo ^a,c   Stepulak, Andrzej ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c ÅBO AKADEMI UNIVERSITY   (Finland)

Author keywords

Cadherin; Catenin; EMT; HDAC; HDI; Invasion; MET; Migration; Vimentin

Indexed keywords

4 PHENYLBUTYRIC ACID; APICIDIN; BELINOSTAT; BETA CATENIN; BUTYRIC ACID; CISPLATIN; DOMATINOSTAT; ENTINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MOCETINOSTAT; NERVE CELL ADHESION MOLECULE; PANOBINOSTAT; PROTEIN ZEB; RESMINOSTAT; RESVERATROL; ROMIDEPSIN; SMAD PROTEIN; TEMOZOLOMIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRICHOSTATIN A; UNCLASSIFIED DRUG; UVOMORULIN; VALPROIC ACID; VIMENTIN; VORINOSTAT;

ACETYLATION; BILE DUCT CARCINOMA; BREAST CANCER; CANCER CELL; CELL INVASION; CELL MIGRATION; CELL STRUCTURE; CELL TRANSFORMATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DRUG EFFECT; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GLIOBLASTOMA; HEAD AND NECK CANCER; HISTONE MODIFICATION; HUMAN; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASM; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERIPHERAL T CELL LYMPHOMA; PHENOTYPE; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; TRANSITIONAL CELL CARCINOMA;

EID: 85061960337     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers11020148     Document Type: Review

References (150)

1. Davis, F.M.; Stewart, T.A.; Thompson, E.W.; Monteith, G.R. Targeting EMT in cancer: Opportunities for pharmacological intervention. Trends Pharmacol. Sci. 2014, 35, 479-488.
2. Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009, 119, 1420-1428.
3. Fardi, M.; Solali, S.; Farshdousti Hagh, M. Epigenetic mechanisms as a new approach in cancer treatment:An updated review. Genes Dis. 2018, 5, 304-311.
4. Ma, F.; Jiang, S.; Zhang, C. Recent advances in histone modification and histone modifying enzyme assays. Expert Rev. Mol. Diagn. 2018, 1-10.
5. Grabarska, A.; Łuszczki, J.J.; Nowosadzka, E.; Gumbarewicz, E.; Jeleniewicz, W.; Dmoszyńska-Graniczka, M.; Kowalczuk, K.; Kupisz, K.; Polberg, K.; Stepulak, A. Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells. J. Cancer 2017, 8, 19-28.
6. Gumbarewicz, E.; Luszczki, J.J.; Wawruszak, A.; Dmoszynska-Graniczka, M.; Grabarska, A.J.; Jarząb, A.M.; Polberg, K.; Stepulak, A. Isobolographic analysis demonstrates additive effect of cisplatin and HDIs combined treatment augmenting their anti-cancer activity in lung cancer cell lines. Am. J. Cancer Res. 2016, 6, 2831-2845.
7. Wawruszak, A.; Luszczki, J.J.; Grabarska, A.; Gumbarewicz, E.; Dmoszynska-Graniczka, M.; Polberg, K.; Stepulak, A. Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines-An Isobolographic Analysis. PLoS ONE 2015, 10, e0143013.
8. Falkenberg, K.J.; Johnstone, R.W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 2014, 13, 673-691.
9. Hölscher, A.S.; Schulz, W.A.; Pinkerneil, M.; Niegisch, G.; Hoffmann, M.J. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines. Clin. Epigenetics 2018, 10, 1.
10. Yao, D.; Dai, C.; Peng, S. Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol. Cancer Res. 2011, 9, 1608-1620.
11. Lan, X.; Lu, G.; Yuan, C.; Mao, S.; Jiang, W.; Chen, Y.; Jin, X.; Xia, Q. Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4. J. Cancer Res. Clin. Oncol. 2016, 142, 177-185.
12. Nalls, D.; Tang, S.-N.; Rodova, M.; Srivastava, R.K.; Shankar, S. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS ONE 2011, 6, e24099.
13. Wang, X.; Xu, J.; Wang, H.; Wu, L.; Yuan, W.; Du, J.; Cai, S. Trichostatin A, a histone deacetylase inhibitor, reverses epithelial-mesenchymal transition in colorectal cancer SW480 and prostate cancer PC3 cells. Biochem. Biophys. Res. Commun. 2015, 456, 320-326.
14. Shah, P.; Gau, Y.; Sabnis, G. Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin. Breast Cancer Res. Treat. 2014, 143, 99-111.
15. Ji, M.; Lee, E.J.; Kim, K.B.; Kim, Y.; Sung, R.; Lee, S.-J.; Kim, D.S.; Park, S.M. HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells. Oncol. Rep. 2015, 33, 2299-2308.
16. Suraweera, A.; O’Byrne, K.J.; Richard, D.J. Combination Therapy with Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. Front. Oncol. 2018, 8, 92.
17. Ronnekleiv-Kelly, S.M.; Sharma, A.; Ahuja, N. Epigenetic therapy and chemosensitization in solid malignancy. Cancer Treat. Rev. 2017, 55, 200-208.
18. Manal, M.; Chandrasekar, M.J.N.; Gomathi Priya, J.; Nanjan, M.J. Inhibitors of histone deacetylase as antitumor agents: A critical review. Bioorg. Chem. 2016, 67, 18-42.
19. Sun, X.-J.; Man, N.; Tan, Y.; Nimer, S.D.; Wang, L. The Role of Histone Acetyltransferases in Normal and Malignant Hematopoiesis. Front. Oncol. 2015, 5, 108.
20. Roche, J.; Bertrand, P. Inside HDACs with more selective HDAC inhibitors. Eur. J. Med. Chem. 2016, 121, 451-483.
21. Yang, X.-J.; Seto, E. HATs and HDACs: From structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007, 26, 5310-5318.
22. Chrun, E.S.; Modolo, F.; Daniel, F.I. Histone modifications: A review about the presence of this epigenetic phenomenon in carcinogenesis. Pathol. Res. Pract. 2017, 213, 1329-1339.
23. Barneda-Zahonero, B.; Parra, M. Histone deacetylases and cancer. Mol. Oncol. 2012, 6, 579-589.
24. He, Y.; Cai, C.; Tang, D.; Sun, S.; Li, H. Effect of histone deacetylase inhibitors trichostatin A and valproic acid on hair cell regeneration in zebrafish lateral line neuromasts. Front. Cell. Neurosci. 2014, 8, 382.
25. Vickers, C.J.; Olsen, C.A.; Leman, L.J.; Ghadiri, M.R. Discovery of HDAC Inhibitors That Lack an Active Site Zn(2+)-Binding Functional Group. ACS Med. Chem. Lett. 2012, 3, 505-508.
26. Dang, W. The controversial world of sirtuins. Drug Discov. Today Technol. 2014, 12, e9-e17.
27. Haberland, M.; Montgomery, R.L.; Olson, E.N. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat. Rev. Genet. 2009, 10, 32-42.
28. Lahm, A.; Paolini, C.; Pallaoro, M.; Nardi, M.C.; Jones, P.; Neddermann, P.; Sambucini, S.; Bottomley, M.J.; Lo Surdo, P.; Carfí, A.; et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc. Natl. Acad. Sci. USA 2007, 104, 17335-17340.
29. Kaletsch, A.; Pinkerneil, M.; Hoffmann, M.J.; Jaguva Vasudevan, A.A.; Wang, C.; Hansen, F.K.; Wiek, C.; Hanenberg, H.; Gertzen, C.; Gohlke, H.; et al. Effects of novel HDAC inhibitors on urothelial carcinoma cells. Clin. Epigenetics 2018, 10, 100.
30. Fischle, W.; Dequiedt, F.; Hendzel, M.J.; Guenther, M.G.; Lazar, M.A.; Voelter, W.; Verdin, E. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 2002, 9, 45-57.
31. Martin, M.; Kettmann, R.; Dequiedt, F. Class IIa histone deacetylases: Regulating the regulators. Oncogene 2007, 26, 5450-5467.
32. Seto, E.; Yoshida, M. Erasers of histone acetylation: The histone deacetylase enzymes. Cold Spring Harb. Perspect. Biol. 2014, 6, a018713.
33. Singh, A.; Bishayee, A.; Pandey, A. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy. Nutrients 2018, 10, 731.
34. Xu, J.; Wang, H.; Huang, G. Histone acetylation and congenital heart diseases. Chinese J. Pediatr. 2013, 51, 552-554.
35. Angiolilli, C.; Baeten, D.L.; Radstake, T.R.; Reedquist, K.A. The acetyl code in rheumatoid arthritis and other rheumatic diseases. Epigenomics 2017, 9, 447-461.
36. Bonnaud, E.M.; Suberbielle, E.; Malnou, C.E. Histone acetylation in neuronal (dys)function. Biomol. Concepts 2016, 7, 103-116.
37. Bayat, S.; Shekari Khaniani, M.; Choupani, J.; Alivand, M.R.; Mansoori Derakhshan, S. HDACis (class I), cancer stem cell, and phytochemicals: Cancer therapy and prevention implications. Biomed. Pharmacother. 2018, 97, 1445-1453.
38. Giaginis, C.; Damaskos, C.; Koutsounas, I.; Zizi-Serbetzoglou, A.; Tsoukalas, N.; Patsouris, E.; Kouraklis, G.; Theocharis, S. Histone deacetylase (HDAC)-1, -2, -4 and -6 expression in human pancreatic adenocarcinoma:Associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival. BMC Gastroenterol. 2015, 15, 148.
39. Shan, W.; Jiang, Y.; Yu, H.; Huang, Q.; Liu, L.; Guo, X.; Li, L.; Mi, Q.; Zhang, K.; Yang, Z. HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer. Am. J. Cancer Res. 2017, 7, 1213-1226.
40. Ramakrishnan, S.; Ku, S.; Ciamporcero, E.; Miles, K.M.; Attwood, K.; Chintala, S.; Shen, L.; Ellis, L.; Sotomayor, P.; Swetzig, W.; et al. HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma. BMC Cancer 2016, 16, 617.
41. Damaskos, C.; Valsami, S.; Kontos, M.; Spartalis, E.; Kalampokas, T.; Kalampokas, E.; Athanasiou, A.; Moris, D.; Daskalopoulou, A.; Davakis, S.; et al. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer. Anticancer Res. 2017, 37, 35-46.
42. Zhang, H.; Shang, Y.-P.; Chen, H.; Li, J. Histone deacetylases function as novel potential therapeutic targets for cancer. Hepatol. Res. 2017, 47, 149-159.
43. Expression of HDAC1 in Cancer-Summary-The Human Protein Atlas. Available online: https://www. proteinatlas.org/ENSG00000116478-HDAC1/pathology (accessed on 10 January 2019).
44. Expression of HDAC2 in Cancer-Summary-The Human Protein Atlas. Available online: https://www. proteinatlas.org/ENSG00000196591-HDAC2/pathology (accessed on 10 January 2019).
45. Expression of HDAC3 in Cancer-Summary-The Human Protein Atlas. Available online: https://www. proteinatlas.org/ENSG00000171720-HDAC3/pathology (accessed on 10 January 2019).
46. Expression of HDAC8 in Cancer-Summary-The Human Protein Atlas. Available online: https://www. proteinatlas.org/ENSG00000147099-HDAC8/pathology (accessed on 10 January 2019).
47. Expression of HDAC4 in Cancer-Summary-The Human Protein Atlas. Available online: https://www. proteinatlas.org/ENSG00000068024-HDAC4/pathology (accessed on 10 January 2019).
48. Expression of HDAC5 in Cancer-Summary-The Human Protein Atlas. Available online: https://www. proteinatlas.org/ENSG00000108840-HDAC5/pathology (accessed on 10 January 2019).
49. Expression of HDAC9 in Cancer-Summary-The Human Protein Atlas. Available online: https://www. proteinatlas.org/ENSG00000048052-HDAC9/pathology (accessed on 10 January 2019).
50. Lei, Y.; Liu, L.; Zhang, S.; Guo, S.; Li, X.; Wang, J.; Su, B.; Fang, Y.; Chen, X.; Ke, H.; et al. Hdac7 promotes lung tumorigenesis by inhibiting Stat3 activation. Mol. Cancer 2017, 16, 170.
51. Expression of HDAC10 in Cancer-Summary-The Human Protein Atlas. Available online: https://www. proteinatlas.org/ENSG00000100429-HDAC10/pathology (accessed on 10 January 2019).
52. Expression of HDAC6 in Cancer-Summary-The Human Protein Atlas. Available online: https://www. proteinatlas.org/ENSG00000094631-HDAC6/pathology (accessed on 10 January 2019).
53. Expression of SIRT3 in Cancer-Summary-The Human Protein Atlas. Available online: https://www. proteinatlas.org/ENSG00000142082-SIRT3/pathology (accessed on 10 January 2019).
54. Expression of SIRT5 in Cancer-Summary-The Human Protein Atlas. Available online: https://www. proteinatlas.org/ENSG00000124523-SIRT5/pathology (accessed on 10 January 2019).
55. Expression of SIRT6 in Cancer-Summary-The Human Protein Atlas. Available online: https://www. proteinatlas.org/ENSG00000077463-SIRT6/pathology (accessed on 10 January 2019).
56. Expression of SIRT7 in Cancer-Summary-The Human Protein Atlas. Available online: https://www. proteinatlas.org/ENSG00000187531-SIRT7/pathology (accessed on 10 January 2019).
57. Expression of SIRT2 in Cancer-Summary-The Human Protein Atlas. Available online: https://www. proteinatlas.org/ENSG00000068903-SIRT2/pathology (accessed on 10 January 2019).
58. Deubzer, H.E.; Schier, M.C.; Oehme, I.; Lodrini, M.; Haendler, B.; Sommer, A.; Witt, O. HDAC11 is a novel drug target in carcinomas. Int. J. Cancer 2013, 132, 2200-2208.
59. Expression of SIRT1 in Cancer-Summary-The Human Protein Atlas. Available online: https://www. proteinatlas.org/ENSG00000096717-SIRT1/pathology (accessed on 10 January 2019).
60. Expression of SIRT4 in Cancer-Summary-The Human Protein Atlas. Available online: https://www. proteinatlas.org/ENSG00000089163-SIRT4/pathology (accessed on 10 January 2019).
61. Niegisch, G.; Knievel, J.; Koch, A.; Hader, C.; Fischer, U.; Albers, P.; Schulz, W.A. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Urol. Oncol. Semin. Orig. Investig. 2013, 31, 1770-1779.
62. Pinkerneil, M.; Hoffmann, M.J.; Deenen, R.; Kohrer, K.; Arent, T.; Schulz, W.A.; Niegisch, G. Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms. Mol. Cancer Ther. 2016, 15, 299-312.
63. Lehmann, M.; Hoffmann, M.J.; Koch, A.; Ulrich, S.M.; Schulz, W.A.; Niegisch, G. Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment. J. Exp. Clin. Cancer Res. 2014, 33, 59.
64. Chervona, Y.; Costa, M. Histone modifications and cancer: Biomarkers of prognosis? Am. J. Cancer Res. 2012, 2, 589-597.
65. Gobinet, J.; Carascossa, S.; Cavaillès, V.; Vignon, F.; Nicolas, J.-C.; Jalaguier, S. SHP represses transcriptional activity via recruitment of histone deacetylases. Biochemistry 2005, 44, 6312-6320.
66. Narita, T.; Weinert, B.T.; Choudhary, C. Functions and mechanisms of non-histone protein acetylation. Nat. Rev. Mol. Cell Biol. 2018.
67. Glozak, M.A.; Sengupta, N.; Zhang, X.; Seto, E. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363, 15-23.
68. Lee, J.S.; Galvin, K.M.; See, R.H.; Eckner, R.; Livingston, D.; Moran, E.; Shi, Y. Relief of YY1 transcriptional repression by adenovirus E1A is mediated by E1A-associated protein p300. Genes Dev. 1995, 9, 1188-1198.
69. Lührs, H.; Hock, R.; Schauber, J.; Weihrauch, M.; Harrer, M.; Melcher, R.; Scheppach, W.; Bustin, M.; Menzel, T. Modulation of HMG-N2 binding to chromatin by butyrate-induced acetylation in human colon adenocarcinoma cells. Int. J. Cancer 2002, 97, 567-573.
70. Edberg, D.D.; Bruce, J.E.; Siems, W.F.; Reeves, R. In Vivo Posttranslational Modifications of the High Mobility Group A1a Proteins in Breast Cancer Cells of Differing Metastatic Potential. Biochemistry 2004, 43, 11500-11515.
71. Gaughan, L.; Logan, I.R.; Cook, S.; Neal, D.E.; Robson, C.N. Tip60 and Histone Deacetylase 1 Regulate Androgen Receptor Activity through Changes to the Acetylation Status of the Receptor. J. Biol. Chem. 2002, 277, 25904-25913.
72. Boyes, J.; Byfield, P.; Nakatani, Y.; Ogryzko, V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 1998, 396, 594-598.
73. Zhang, W.; Bieker, J.J. Acetylation and modulation of erythroid Krüppel-like factor (EKLF) activity by interaction with histone acetyltransferases. Proc. Natl. Acad. Sci. USA 1998, 95, 9855-9860.
74. Chen, L.; Mu, Y.; Greene, W.C. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J. 2002, 21, 6539-6548.
75. Bali, P.; Pranpat, M.; Bradner, J.; Balasis, M.; Fiskus, W.; Guo, F.; Rocha, K.; Kumaraswamy, S.; Boyapalle, S.; Atadja, P.; et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 2005, 280, 26729-26734.
76. Jeong, J.W.; Bae, M.K.; Ahn, M.Y.; Kim, S.H.; Sohn, T.K.; Bae, M.H.; Yoo, M.A.; Song, E.J.; Lee, K.J.; Kim, K.W. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002, 111, 709-720.
77. Simonsson, M.; Heldin, C.-H.; Ericsson, J.; Grönroos, E. The balance between acetylation and deacetylation controls Smad7 stability. J. Biol. Chem. 2005, 280, 21797-21803.
78. Jin, K.; Zhou, W.; Han, X.; Wang, Z.; Li, B.; Jeffries, S.; Tao, W.; Robbins, D.J.; Capobianco, A.J. Acetylation of Mastermind-like 1 by p300 Drives the Recruitment of NACK to Initiate Notch-Dependent Transcription. Cancer Res. 2017, 77, 4228-4237.
79. Zhao, D.; Mo, Y.; Li, M.-T.; Zou, S.-W.; Cheng, Z.-L.; Sun, Y.-P.; Xiong, Y.; Guan, K.-L.; Lei, Q.-Y. NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells. J. Clin. Investig. 2014, 124, 5453-5465.
80. Pinkerneil, M.; Hoffmann, M.J.; Kohlhof, H.; Schulz, W.A.; Niegisch, G. Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines. Target. Oncol. 2016, 11, 783-798.
81. Qiu, X.; Xiao, X.; Li, N.; Li, Y. Histone deacetylases inhibitors (HDACis) as novel therapeutic application in various clinical diseases. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2017, 72, 60-72.
82. Tasoulas, J.; Giaginis, C.; Patsouris, E.; Manolis, E.; Theocharis, S. Histone deacetylase inhibitors in oral squamous cell carcinoma treatment. Expert Opin. Investig. Drugs 2015, 24, 69-78.
83. Kumar, S.; Tandon, N.; Ramakrishnan, V. Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. Clin. Pharmacol. Adv. Appl. 2016, 8, 35.
84. Kusaczuk, M.; Krętowski, R.; Bartoszewicz, M.; Cechowska-Pasko, M. Phenylbutyrate-a pan-HDAC inhibitor-suppresses proliferation of glioblastoma LN-229 cell line. Tumour Biol. 2016, 37, 931-942.
85. Park, M.J.; Sohrabji, F. The histone deacetylase inhibitor, sodium butyrate, exhibits neuroprotective effects for ischemic stroke in middle-aged female rats. J. Neuroinflamm. 2016, 13, 300.
86. Leng, Y.; Wang, J.; Wang, Z.; Liao, H.-M.; Wei, M.; Leeds, P.; Chuang, D.-M. Valproic Acid and Other HDAC Inhibitors Upregulate FGF21 Gene Expression and Promote Process Elongation in Glia by Inhibiting HDAC2 and 3. Int. J. Neuropsychopharmacol. 2016, 19.
87. Zhou, W.; Feng, X.; Han Han, H.; Guo, S.; Wang, G. Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells. Sci. Rep. 2016, 6, 28004.
88. Foss, F.; Advani, R.; Duvic, M.; Hymes, K.B.; Intragumtornchai, T.; Lekhakula, A.; Shpilberg, O.; Lerner, A.; Belt, R.J.; Jacobsen, E.D.; et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br. J. Haematol. 2015, 168, 811-819.
89. Wightman, F.; Lu, H.K.; Solomon, A.E.; Saleh, S.; Harman, A.N.; Cunningham, A.L.; Gray, L.; Churchill, M.; Cameron, P.U.; Dear, A.E.; et al. Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. AIDS 2013, 27, 2853-2862.
90. Zhang, Q.; Sun, M.; Zhou, S.; Guo, B. Class I HDAC inhibitor mocetinostat induces apoptosis by activation of miR-31 expression and suppression of E2F6. Cell Death Discov. 2016, 2, 16036.
91. Petrich, A.; Nabhan, C. Use of class I histone deacetylase inhibitor romidepsin in combination regimens. Leuk. Lymphoma 2016, 57, 1755-1765.
92. Igotti Abramova, M.V.; Pojidaeva, A.K.; Filippova, E.A.; Gnedina, O.O.; Svetlikova, S.B.; Pospelov, V.A. HDAC inhibitors induce apoptosis but not cellular senescence in Gadd45β-deficient E1A+Ras cells. Int. J. Biochem. Cell Biol. 2014, 51, 102-110.
93. Bao, L.; Diao, H.; Dong, N.; Su, X.; Wang, B.; Mo, Q.; Yu, H.; Wang, X.; Chen, C. Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation. Cell Biol. Toxicol. 2016, 32, 469-482.
94. Stepulak, A.; Stryjecka-Zimmer, M.; Kupisz, K.; Polberg, K. Histone deacetylase inhibitors as a new generation of anti-cancer agents. Postepy Hig. Med. Dosw. 2005, 59, 68-74.
95. Osuka, S.; Takano, S.; Watanabe, S.; Ishikawa, E.; Yamamoto, T.; Matsumura, A. Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain. Neurol. Med. Chir. 2012, 52, 186-193.
96. VanderMolen, K.M.; McCulloch, W.; Pearce, C.J.; Oberlies, N.H. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): A natural product recently approved for cutaneous T-cell lymphoma. J. Antibiot. 2011, 64, 525-531.
97. Kim, E.; Bisson, W.H.; Löhr, C.V.; Williams, D.E.; Ho, E.; Dashwood, R.H.; Rajendran, P. Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors. Curr. Top. Med. Chem. 2016, 16, 714-731.
98. Gurzu, S.; Turdean, S.; Kovecsi, A.; Contac, A.O.; Jung, I. Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: An update. World J. Clin. Cases 2015, 3, 393.
99. Barriere, G.; Fici, P.; Gallerani, G.; Fabbri, F.; Rigaud, M. Epithelial Mesenchymal Transition: A double-edged sword. Clin. Transl. Med. 2015, 4, 14.
100. Huang, R.Y.-J.; Guilford, P.; Thiery, J.P. Early events in cell adhesion and polarity during epithelial-mesenchymal transition. J. Cell Sci. 2012, 125, 4417-4422.
101. Nieto, M.A.; Huang, R.Y.-J.; Jackson, R.A.; Thiery, J.P. EMT: 2016. Cell 2016, 166, 21-45.
102. Lamouille, S.; Xu, J.; Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014, 15, 178-196.
103. Francart, M.-E.; Lambert, J.; Vanwynsberghe, A.M.; Thompson, E.W.; Bourcy, M.; Polette, M.; Gilles, C. Epithelial-mesenchymal plasticity and circulating tumor cells: Travel companions to metastases. Dev. Dyn. 2018, 247, 432-450.
104. Liu, C.-Y.; Lin, H.-H.; Tang, M.-J.; Wang, Y.-K. Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation. Oncotarget 2015, 6, 15966-15983.
105. Wong, S.H.M.; Fang, C.M.; Chuah, L.-H.; Leong, C.O.; Ngai, S.C. E-cadherin: Its dysregulation in carcinogenesis and clinical implications. Crit. Rev. Oncol. Hematol. 2018, 121, 11-22.
106. Skrypek, N.; Goossens, S.; De Smedt, E.; Vandamme, N.; Berx, G. Epithelial-to-Mesenchymal Transition:Epigenetic Reprogramming Driving Cellular Plasticity. Trends Genet. 2017, 33, 943-959.
107. Wang, Y.; Shi, J.; Chai, K.; Ying, X.; Zhou, B.P. The Role of Snail in EMT and Tumorigenesis. Curr. Cancer Drug Targets 2013, 13, 963-972.
108. Gheldof, A.; Hulpiau, P.; van Roy, F.; De Craene, B.; Berx, G. Evolutionary functional analysis and molecular regulation of the ZEB transcription factors. Cell. Mol. Life Sci. 2012, 69, 2527-2541.
109. Garg, M. Epithelial, mesenchymal and hybrid epithelial/mesenchymal phenotypes and their clinical relevance in cancer metastasis. Expert Rev. Mol. Med. 2017, 19, e3.
110. Lo, H.C.; Zhang, X.H.-F. EMT in Metastasis: Finding the Right Balance. Dev. Cell 2018, 45, 663-665.
111. Pastushenko, I.; Brisebarre, A.; Sifrim, A.; Fioramonti, M.; Revenco, T.; Boumahdi, S.; Van Keymeulen, A.; Brown, D.; Moers, V.; Lemaire, S.; et al. Identification of the tumour transition states occurring during EMT. Nature 2018, 556, 463-468.
112. Jolly, M.K.; Boareto, M.; Debeb, B.G.; Aceto, N.; Farach-Carson, M.C.; Woodward, W.A.; Levine, H. Inflammatory breast cancer: A model for investigating cluster-based dissemination. NPJ Breast Cancer 2017, 3, 21.
113. Tang, H.M.; Kuay, K.T.; Koh, P.F.; Asad, M.; Tan, T.Z.; Chung, V.Y.; Lee, S.C.; Thiery, J.P.; Huang, R.-J. An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers. Cell Death Discov. 2016, 2, 16041.
114. Nagaraja, S.S.; Krishnamoorthy, V.; Raviraj, R.; Paramasivam, A.; Nagarajan, D. Effect of Trichostatin A on radiation induced epithelial-mesenchymal transition in A549 cells. Biochem. Biophys. Res. Commun. 2017, 493, 1534-1541.
115. Park, I.-H.; Kang, J.-H.; Shin, J.-M.; Lee, H.-M. Trichostatin A Inhibits Epithelial Mesenchymal Transition Induced by TGF-α1 in Airway Epithelium. PLoS ONE 2016, 11, e0162058.
116. Mateen, S.; Raina, K.; Agarwal, C.; Chan, D.; Agarwal, R. Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells. J. Pharmacol. Exp. Ther. 2013, 345, 206-214.
117. Noguchi, S.; Eitoku, M.; Moriya, S.; Kondo, S.; Kiyosawa, H.; Watanabe, T.; Suganuma, N. Regulation of Gene Expression by Sodium Valproate in Epithelial-to-Mesenchymal Transition. Lung 2015, 193, 691-700.
118. Wang, J.; Xu, M.; Jiang, X.; Mei, X.; Liu, X. Histone deacetylase inhibitor SAHA-induced epithelial-mesenchymal transition by upregulating Slug in lung cancer cells. Anticancer Drugs 2018, 29, 80-88.
119. Wu, Y.; Lyu, H.; Liu, H.; Shi, X.; Song, Y.; Liu, B. Downregulation of the long noncoding RNA GAS5-AS1 contributes to tumor metastasis in non-small cell lung cancer. Sci. Rep. 2016, 6, 31093.
120. Yang, L.; Chang, Y.; Cao, P. CCR7 preservation via histone deacetylase inhibition promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells. Exp. Cell Res. 2018, 371, 231-237.
121. Xu, W.; Liu, H.; Liu, Z.-G.; Wang, H.-S.; Zhang, F.; Wang, H.; Zhang, J.; Chen, J.-J.; Huang, H.-J.; Tan, Y.; et al. Histone deacetylase inhibitors upregulate Snail via Smad2/3 phosphorylation and stabilization of Snail to promote metastasis of hepatoma cells. Cancer Lett. 2018, 420, 1-13.
122. Song, X.; Wang, J.; Zheng, T.; Song, R.; Liang, Y.; Bhatta, N.; Yin, D.; Pan, S.; Liu, J.; Jiang, H.; et al. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway. Mol. Cancer 2013, 12, 114.
123. Soukupova, J.; Bertran, E.; Peñuelas-Haro, I.; Urdiroz-Urricelqui, U.; Borgman, M.; Kohlhof, H.; Fabregat, I. Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis. Oncotarget 2017, 8, 110367-110379.
124. Wang, J.; Lee, E.; Ji, M.; Park, S. HDAC inhibitors, trichostatin A and valproic acid, increase E-cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells. Oncol. Rep. 2018, 40, 346-354.
125. Mishra, V.K.; Wegwitz, F.; Kosinsky, R.L.; Sen, M.; Baumgartner, R.; Wulff, T.; Siveke, J.T.; Schildhaus, H.-U.; Najafova, Z.; Kari, V.; et al. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner. Nucleic Acids Res. 2017, 45, 6334-6349.
126. Polireddy, K.; Dong, R.; McDonald, P.R.; Wang, T.; Luke, B.; Chen, P.; Broward, M.; Roy, A.; Chen, Q. Targeting Epithelial-Mesenchymal Transition for Identification of Inhibitors for Pancreatic Cancer Cell Invasion and Tumor Spheres Formation. PLoS ONE 2016, 11, e0164811.
127. Meidhof, S.; Brabletz, S.; Lehmann, W.; Preca, B.-T.; Mock, K.; Ruh, M.; Schüler, J.; Berthold, M.; Weber, A.; Burk, U.; et al. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol. Med. 2015, 7, 831-847.
128. Lazarova, D.; Bordonaro, M. ZEB1 Mediates Drug Resistance and EMT in p300-Deficient CRC. J. Cancer 2017, 8, 1453-1459.
129. Chen, C.-H.; Lee, C.-H.; Liou, J.-P.; Teng, C.-M.; Pan, S.-L. Molecular mechanisms underlying the antitumor activity of (E)-N-hydroxy-3-(1-(4-methoxyphenylsulfonyl)-1, 2, 3, 4-tetrahydroquinolin-6-yl)acrylamide in human colorectal cancer cells in vitro and in vivo. Oncotarget 2015, 6, 35991-36002.
130. Kiweler, N.; Brill, B.; Wirth, M.; Breuksch, I.; Laguna, T.; Dietrich, C.; Strand, S.; Schneider, G.; Groner, B.; Butter, F.; et al. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells. Arch. Toxicol. 2018, 92, 2227-2243.
131. Choi, S.Y.; Kee, H.J.; Kurz, T.; Hansen, F.K.; Ryu, Y.; Kim, G.R.; Lin, M.Q.; Jin, L.; Piao, Z.H.; Jeong, M.H. Class I HDACs specifically regulate E-cadherin expression in human renal epithelial cells. J. Cell. Mol. Med. 2016, 20, 2289-2298.
132. Skowron, M.A.; Sathe, A.; Romano, A.; Hoffmann, M.J.; Schulz, W.A.; van Koeveringe, G.A.; Albers, P.; Nawroth, R.; Niegisch, G. Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma. Urol. Oncol. Semin. Orig. Investig. 2017, 35, 544.e11-544.e23.
133. Elshafae, S.M.; Kohart, N.A.; Altstadt, L.A.; Dirksen, W.P.; Rosol, T.J. The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis. Prostate 2017, 77, 776-793.
134. McLeod, A.B.; Stice, J.P.; Wardell, S.E.; Alley, H.M.; Chang, C.; McDonnell, D.P. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer. Prostate 2018, 78, 266-277.
135. Sakamoto, T.; Kobayashi, S.; Yamada, D.; Nagano, H.; Tomokuni, A.; Tomimaru, Y.; Noda, T.; Gotoh, K.; Asaoka, T.; Wada, H.; et al. A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer. PLoS ONE 2016, 11, e0145985.
136. Wu, S.; Luo, Z.; Yu, P.-J.; Xie, H.; He, Y.-W. Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8/FOXA1 signals. Biol. Chem. 2016, 397.
137. Debeb, B.G.; Lacerda, L.; Xu, W.; Larson, R.; Solley, T.; Atkinson, R.; Sulman, E.P.; Ueno, N.T.; Krishnamurthy, S.; Reuben, J.M.; et al. Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/β-catenin signaling. Stem Cells 2012, 30, 2366-2377.
138. Rhodes, L.V.; Tate, C.R.; Segar, H.C.; Burks, H.E.; Phamduy, T.B.; Hoang, V.; Elliott, S.; Gilliam, D.; Pounder, F.N.; Anbalagan, M.; et al. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Res. Treat. 2014, 145, 593-604.
139. Srivastava, R.K.; Kurzrock, R.; Shankar, S. MS-275 Sensitizes TRAIL-Resistant Breast Cancer Cells, Inhibits Angiogenesis and Metastasis, and Reverses Epithelial-Mesenchymal Transition In vivo. Mol. Cancer Ther. 2010, 9, 3254-3266.
140. Meng, F.; Sun, G.; Zhong, M.; Yu, Y.; Brewer, M.A. Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2'-deoxycytidine on ovarian cancer. Br. J. Cancer 2013, 108, 579-586.
141. Bruzzese, F.; Leone, A.; Rocco, M.; Carbone, C.; Piro, G.; Caraglia, M.; Di Gennaro, E.; Budillon, A. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J. Cell. Physiol. 2011, 226, 2378-2390.
142. Kanamoto, A.; Ninomiya, I.; Harada, S.; Tsukada, T.; Okamoto, K.; Nakanuma, S.; Sakai, S.; Makino, I.; Kinoshita, J.; Hayashi, H.; et al. Valproic acid inhibits irradiation-induced epithelial-mesenchymal transition and stem cell-like characteristics in esophageal squamous cell carcinoma. Int. J. Oncol. 2016, 49, 1859-1869.
143. Choi, E.J.; Cho, B.J.; Lee, D.J.; Hwang, Y.H.; Chun, S.H.; Kim, H.H.; Kim, I.A. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: Targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases. BMC Cancer 2014, 14, 17.
144. Shankar, S.; Nall, D.; Tang, S.-N.; Meeker, D.; Passarini, J.; Sharma, J.; Srivastava, R.K. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS ONE 2011, 6, e16530.
145. Yoshikawa, M.; Hishikawa, K.; Marumo, T.; Fujita, T. Inhibition of Histone Deacetylase Activity Suppresses Epithelial-to-Mesenchymal Transition Induced by TGF-beta1 in Human Renal Epithelial Cells. J. Am. Soc. Nephrol. 2007, 18, 58-65.
146. Ruscetti, M.; Dadashian, E.L.; Guo, W.; Quach, B.; Mulholland, D.J.; Park, J.W.; Tran, L.M.; Kobayashi, N.; Bianchi-Frias, D.; Xing, Y.; et al. HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer. Oncogene 2016, 35, 3781-3795.
147. Sarkar, S.; Goldgar, S.; Byler, S.; Rosenthal, S.; Heerboth, S. Demethylation and re-expression of epigenetically silenced tumor suppressor genes: Sensitization of cancer cells by combination therapy. Epigenomics 2013, 5, 87-94.
148. Kazanets, A.; Shorstova, T.; Hilmi, K.; Marques, M.; Witcher, M. Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential. Biochim. Biophys. Acta Rev. Cancer 2016, 1865, 275-288.
149. Lefter, L.P.; Dima, S.; Sunamura, M.; Furukawa, T.; Sato, Y.; Abe, M.; Chivu, M.; Popescu, I.; Horii, A. Transcriptional silencing of ETS-1 efficiently suppresses angiogenesis of pancreatic cancer. Cancer Gene Ther. 2009, 16, 137-148.
150. Avgustinova, A.; Symeonidi, A.; Castellanos, A.; Urdiroz-Urricelqui, U.; Solé-Boldo, L.; Martín, M.; Pérez-Rodríguez, I.; Prats, N.; Lehner, B.; Supek, F.; et al. Loss of G9a preserves mutation patterns but increases chromatin accessibility, genomic instability and aggressiveness in skin tumours. Nat. Cell Biol. 2018, 20, 1400-1409.